This concerning trend is gaining momentum: major hospital networks are increasingly resistant to adopting innovative orthopedic devices. Metaphorically speaking, these systems have developed "antibodies" that fend off new products, prioritizing cost control and evidence-based value over rapid innovation.
This shift, driven by consolidation and rigorous evaluation processes, poses significant challenges for device manufacturers and sales teams.At the heart of this resistance is the rise of the Value Analysis Committee (VAC) era. Gone are the days when surgeons held sway over purchasing decision...
